COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Hydroxychloroquine and Azithromycin as Prophylaxis for Healthcare Workers Dealing With COVID19 Patients (MOPHYDA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04354597
Recruitment Status : Not yet recruiting
First Posted : April 21, 2020
Last Update Posted : May 5, 2020
Information provided by (Responsible Party):
Iyad Sultan, King Hussein Cancer Center

Brief Summary:
The main objective of this study is to assess the efficacy of the combination hydroxychloroquine and Azithromycin (HCQ and AZ) in reducing the infection risk among health care professionals in direct contact with COVID-19 patients.

Condition or disease Intervention/treatment Phase
COVID-19 Drug: HCQ & AZ Not Applicable

Detailed Description:

Exceptional efforts have been paid globally to apply the latest and most effective means of universal standard precautions throughout the settings facing COVID-19 crisis, and this is led by health care providers who are more vulnerable and have a higher risk of getting the infection (8.3% in Italy) and a higher rate of complications and mortality with some reports suggesting high mortality among these individuals.

While several clinical trials are underway across the globe to examine the effect of chloroquine at the moment, the number of COVID-19 cases is still on the rise and health care workers are facing a very high risk of getting the infection. In this study, we aim to study prophylactic efficacy of the combination (HCQ and AZ) among health care professionals in a 16 weeks period.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

Subjects who are enrolled in the study will be randomly assigned to any of the study arms, A or B.

Study Arm A (HCQ & AZ)

Study Arm B (No treatment)

Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Multicenter, Open-label, Pilot Study on Using Hydroxychloroquine (HCQ) and Azithromycin (AZ) Prophylaxis for Healthcare Workers With a Potential Risk of Exposure to COVID-19 Patients
Estimated Study Start Date : May 1, 2020
Estimated Primary Completion Date : August 15, 2020
Estimated Study Completion Date : October 15, 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Study Arm A (HCQ & AZ)
Subjects will receive weekly HCQ 400mg X 1 Day PO and AZ 500mg PO X 3 Days; weekly for 16 weeks.
Drug: HCQ & AZ
Subjects will receive weekly HCQ 400mg PO and AZ PO 500mg X 3 Days; weekly for 16 weeks.

No Intervention: Study Arm B (No treatment)
Subjects will receive no treatment in this group and will be serving as control.

Primary Outcome Measures :
  1. Effect of HCQ and AZ in preventing infection with COVID-19 among healthcare workers working with COVID-19 patients [ Time Frame: 4 Months ]
    Compare the proportion of participants who have RT-PCR confirmed infection with SARS-CoV-2 in both arms during the study period, measured by negative PCR test for SARS COV-2 virus

Secondary Outcome Measures :
  1. Safety of HCQ and AZ [ Time Frame: 4 Months ]
    Solicited and unsolicited adverse events in participants receiving HCQ+AZ during the study period, measured by the incidence of AEs in both arms. (The difference in type, number, and intensity)

  2. Oxygen requirement [ Time Frame: 4 Months ]
    The proportion of participants who require oxygen therapy for any indication during the study period in both arms, measured by the requirement for O2 or not in both arms.

  3. ICU admission [ Time Frame: 4 Months ]
    The proportion of participants who need ICU admission for any reason during the study period in both arms, measured by the incidence of ICU admission in both arms.

  4. Mortality rate [ Time Frame: 4 Months ]
    The proportion of participants who die of any cause during the study period in both arms, measured by the incidence of death in both arms.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   25 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Medical doctors, Nurses and Respiratory therapists caring for COVID-19 patients in ER and ICU and dedicated COVID19 units.
  • Age between 18 and 70 years old.
  • Male or non-pregnant, non- lactating female.
  • Availability for follow up by phone.
  • Willing to participate and provide signed informed consent.

Exclusion Criteria:

  • Subjects with a history of retinopathy, sickle cell disease or trait, psoriasis, or porphyria.
  • Subjects who take certain prescribed or over the counter (OTC) concomitant medication including ampicillin, cimetidine, digoxin, statins, cyclosporine, warfarin, fluconazole, within 2 weeks of dosing start, and during the duration of the study.
  • Current Symptoms of Fever, Cough, or Shortness of Breath.
  • PCR confirmed positive test of COVID-19.
  • Weight < 40 kg.
  • Pregnant (positive β-human chorionic gonadotropin test, β-HCG) or lactating female at the screening.
  • Allergy to any of the study medications.
  • History of splenectomy.
  • Infection with hepatitis B or C viruses.
  • Chronic or active neurologic disease including seizure disorder and chronic migraine headaches.
  • Any abnormal baseline laboratory screening tests listed below

    • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT)above twice the upper limit of normal for the reference lab.
    • Creatinine above the normal range.
    • Hemoglobin for males <12.5 g/dl and females <10.5 g/dl.
    • Platelet count of <150 X 103/L.
    • Total white blood cell (WBC) count out of normal range Note: If screening lab values are out of the normal range but are expected to be temporary (e.g. due to dehydration), they may be re-assessed one more time at the discretion of the investigator.
  • An abnormal baseline screening ECG suggestive of cardiac disease as determined by a clinical investigator. QTcF of >450 msec for males and >470 msec for females.
  • Any other significant finding that based on the judgment of the PI would increase the risk of having an adverse outcome from participating in this study
  • Subjects known to have a mental illness
  • Subjects who have Skin disorders (including rash, dermatitis, and psoriasis)
  • Hematological disease.
  • Cardiovascular disease.
  • G6PD deficiency.
  • Lactose intolerance.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04354597

Layout table for location contacts
Contact: Iyad Sultan, MD +96265300460 ext 1857
Contact: Nedal Al-Rawashdeh, MPH +9627777724198

Layout table for location information
King Hussein Cancer Center
Amman, Jordan
Contact: Iyad Sultan, MD   
Contact: Nedal Al-Rawashdeh, MPH   
Principal Investigator: Iyad Sultan, MD         
Sub-Investigator: Hikmat Abdel-Razeq, MD         
Sub-Investigator: Osama Abu Ata, MD         
Sub-Investigator: Amal Al Omari, PhD         
Sub-Investigator: Lama Nazer, PharmD         
Sub-Investigator: Rana Damsees, MPH         
Sub-Investigator: Dalia Al Rimawi, MDS         
Sub-Investigator: Iyad Al-Ammouri, MD         
Sponsors and Collaborators
King Hussein Cancer Center
Layout table for additonal information
Responsible Party: Iyad Sultan, Chairman- Department of Pediatrics, Pediatrics Administration, King Hussein Cancer Center Identifier: NCT04354597    
Other Study ID Numbers: 20 KHCC 67
First Posted: April 21, 2020    Key Record Dates
Last Update Posted: May 5, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Iyad Sultan, King Hussein Cancer Center: